Abstract #0578

Detection of Aggressive Prostate Cancer Using Extradomain-B Fibronectin Targeted MRI Contrast Agent

Zheng Han¹, Yajuan Li¹, and Zheng-Rong Lu¹

¹Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States

Prostate cancer (PCa) is the second most lethal cancer in American men with a high incidence rate. Current method of PCa screening is not specific to aggressive cancer type, which results in overtreatment with serious adverse effects. We developed a MRI contrast agent, ZD2-Gd(HP-DO3A), that targets to overexpressed extradomain-B in aggressive PCa. Our result showed an increased sensitivity for MRI detection of aggressive PCa using ZD2-Gd(HP-DO3A), compared with the clinical control agent ProHance®. This contrast agent can potentially facilitate accurate risk stratification and clinical management of PCa.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.